Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164616 | 1.00 | LMNA (0.67) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1271236 | 1.00 | LMNA (0.67) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL27882748 | 1.00 | LMNA (0.67) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL530337 | 1.00 | LMNA (0.67) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8108955 | 1.00 | LMNA (0.67) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| Water SCHEMBL8429009 | 0.98 | LMNA (0.65) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28442347 | 0.98 | LMNA (0.65) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL28736318 | 0.89 | LMNA (0.61) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL28736239 | 0.89 | SMN1; SMN2 (0.61) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL28736268 | 0.89 | NPC1 (0.61) | LMNAHPGDHDAC1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-8835473-B2 | Methods and compositions for treating cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-09-16 | — | — | US | claimed |
| US-20120136335-A1 | FOCAL MEDICATION TITRATION SYSTEM | HOBBS JONATHAN P (US) | 2012-05-31 | — | — | US | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-20100221246-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2010-09-02 | — | — | US | claimed |
| US-7307148-B2 | Method for purification of albumin conjugates | CONJUCHEM BIOTECHNOLOGIES INC. (CA) | 2007-12-11 | — | — | US | claimed |
| US-6593482-B2 | (2R,3S)-3-benzoyl-2-hydroxy-3-phenylpropionate of 4,10-beta-diacetoxy-2 alpha-benzoyloxy-5 beta ,20-epoxy-1,13-alpha-dihydroxy-7-beta-methylthiomethyloxy-9-oxo-tax-11-ene from baccatin and beta-lactam | AVENTIS PHARMA S.A. (FR) | 2003-07-15 | — | — | US | claimed |
| EP-0805806-B1 | METHOD FOR PREPARING 4,10-DIACETOXY-2ALFA-BENZOYLOXY-5BETA,20-EPOXY-1,7BETA-DIHYDROXY-9-OXO-TAX-11-EN-13ALFA-YL (2R,3S)-3-BENZOYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE | RHONE POULENC RORER SA (FR) | 1999-12-15 | — | — | EP | claimed |
| US-6002022-A | Method for preparing 4, 10-diacetoxy-2α-benzoyloxy-5β, 20-Epoxy-1, 7β-dihydroxy-9-oxo-tax-11-en-13α-yl(2R,3S)-3-benzoylamino-2-h ydroxy-3-phenylpropionate trihydrate | RHONE-POULENC RORER S.A. (FR) | 1999-12-14 | — | — | US | claimed |
| US-5817867-A | Reduction and resolution methods for the preparation of compounds useful as intermediates for preparing taxanes | BRISTOL-MYERS SQUIBB CO. (US) | 1998-10-06 | — | — | US | claimed |
| EP-0805806-A1 | METHOD FOR PREPARING 4,10-DIACETOXY-2ALFA-BENZOYLOXY-5BETA,20-EPOXY-1,7BETA-DIHYDROXY-9-OXO-TAX-11-EN-13ALFA-YL (2R,3S)-3-BENZOYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE | Aventis Pharma S.A. (FR) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022984-A9 | METHOD FOR PREPARING 4,10-DIACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β-DIHYDROXY-9-OXO-TAX-11-EN-13α-YL (2R,3S)-3-BENZOYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE | — | 1996-10-31 | — | — | WO | claimed |
| WO-1996022984-A1 | METHOD FOR PREPARING 4,10-DIACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β-DIHYDROXY-9-OXO-TAX-11-EN-13α-YL (2R,3S)-3-BENZOYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE | RHONE-POULENC RORER S.A. (FR) | 1996-08-01 | — | — | WO | claimed |
| WO-1995008994-A1 | ANTINEOPLASTIC COMBINATION OF TAXOL AND TIAZOFURIN | INDIANA UNIVERSITY FOUNDATION (US) | 1995-04-06 | — | — | WO | claimed |
| WO-1993010076-A1 | SYNTHESIS AND OPTICAL RESOLUTION OF THE TAXOL SIDE CHAIN AND RELATED COMPOUNDS | THE UNIVERSITY OF MISSISSIPPI (US) | 1993-05-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | LMNA 4734/4885HPGD 3676/4885HDAC1 1959/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | LMNA 4734/4885HPGD 3676/4885HDAC1 1959/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | LMNA 4734/4885HPGD 3676/4885HDAC1 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.